Search Results - "Minna, John D."

Small-cell lung cancer: what we know, what we need to know and the path forward by Gazdar, Adi F., Bunn, Paul A., Minna, John D.

“…Key Points Small-cell lung cancer (SCLC) is a deadly cancer associated with smoke exposure that has neuroendocrine (NE) cell properties and is pathologically,…”
Get full text

Mechanical regulation of glycolysis via cytoskeleton architecture by Park, Jin Suk, Burckhardt, Christoph J., Lazcano, Rossana, Solis, Luisa M., Isogai, Tadamoto, Li, Linqing, Chen, Christopher S., Gao, Boning, Minna, John D., Bachoo, Robert, DeBerardinis, Ralph J., Danuser, Gaudenz

“…The mechanics of the cellular microenvironment continuously modulates cell functions such as growth, survival, apoptosis, differentiation and morphogenesis via…”
Get full text

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs by Borromeo, Mark D., Savage, Trisha K., Kollipara, Rahul K., He, Min, Augustyn, Alexander, Osborne, Jihan K., Girard, Luc, Minna, John D., Gazdar, Adi F., Cobb, Melanie H., Johnson, Jane E.

“…Small cell lung carcinoma (SCLC) is a high-grade pulmonary neuroendocrine tumor. The transcription factors ASCL1 and NEUROD1 play crucial roles in promoting…”
Get full text

Small cell lung cancer: will recent progress lead to improved outcomes? by Pietanza, M Catherine, Byers, Lauren Averett, Minna, John D, Rudin, Charles M

“…Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth…”
Get full text

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time by Gerber, David E., Minna, John D.

“…It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer…”
Get full text

Molecular Biology of Lung Cancer: Clinical Implications by Larsen, Jill E., PhD, Minna, John D., MD

“…Lung cancer is a heterogeneous disease clinically, biologically, histologically, and molecularly. Understanding the molecular causes of this heterogeneity,…”
Get full text

Lung Cancer Computational Biology and Resources by Cai, Ling, Xiao, Guanghua, Gerber, David, D Minna, John, Xie, Yang

“…Comprehensive clinical, pathological, and molecular data, when appropriately integrated with advanced computational approaches, are transforming the way we…”
Get full text

ZEB1 drives epithelial-to-mesenchymal transition in lung cancer by Larsen, Jill E, Nathan, Vaishnavi, Osborne, Jihan K, Farrow, Rebecca K, Deb, Dhruba, Sullivan, James P, Dospoy, Patrick D, Augustyn, Alexander, Hight, Suzie K, Sato, Mitsuo, Girard, Luc, Behrens, Carmen, Wistuba, Ignacio I, Gazdar, Adi F, Hayward, Nicholas K, Minna, John D

“…Increased expression of zinc finger E-box binding homeobox 1 (ZEB1) is associated with tumor grade and metastasis in lung cancer, likely due to its role as a…”
Get full text

Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis by Padanad, Mahesh S., Konstantinidou, Georgia, Venkateswaran, Niranjan, Melegari, Margherita, Rindhe, Smita, Mitsche, Matthew, Yang, Chendong, Batten, Kimberly, Huffman, Kenneth E., Liu, Jingwen, Tang, Ximing, Rodriguez-Canales, Jaime, Kalhor, Neda, Shay, Jerry W., Minna, John D., McDonald, Jeffrey, Wistuba, Ignacio I., DeBerardinis, Ralph J., Scaglioni, Pier Paolo

“…KRAS is one of the most commonly mutated oncogenes in human cancer. Mutant KRAS aberrantly regulates metabolic networks. However, the contribution of cellular…”
Get full text

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery by Kao, Jessica, Salari, Keyan, Bocanegra, Melanie, Choi, Yoon-La, Girard, Luc, Gandhi, Jeet, Kwei, Kevin A, Hernandez-Boussard, Tina, Wang, Pei, Gazdar, Adi F, Minna, John D, Pollack, Jonathan R

“…Breast cancer cell lines have been used widely to investigate breast cancer pathobiology and new therapies. Breast cancer is a molecularly heterogeneous…”
Get full text

Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions by Pelosof, Lorraine, Ahn, Chul, Gao, Ang, Horn, Leora, Madrigales, Alejandra, Cox, Joan, McGavic, Dauphne, Minna, John D, Gazdar, Adi F, Schiller, Joan

“…Approximately 10% to 15% of lung cancer cases in the United States occur in never smokers, but there has been much debate about whether this rate is…”
Get full text

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells by Chen, Pei-Hsuan, Cai, Ling, Huffman, Kenneth, Yang, Chendong, Kim, Jiyeon, Faubert, Brandon, Boroughs, Lindsey, Ko, Bookyung, Sudderth, Jessica, McMillan, Elizabeth A., Girard, Luc, Chen, Dong, Peyton, Michael, Shields, Misty D., Yao, Bo, Shames, David S., Kim, Hyun Seok, Timmons, Brenda, Sekine, Ikuo, Britt, Rebecca, Weber, Stephanie, Byers, Lauren A., Heymach, John V., Chen, Jing, White, Michael A., Minna, John D., Xiao, Guanghua, DeBerardinis, Ralph J.

“…Intermediary metabolism in cancer cells is regulated by diverse cell-autonomous processes, including signal transduction and gene expression patterns, arising…”
Get full text

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer by CARDNELL, Robert J, YING FENG, BYERS, Lauren A, LIXIA DIAO, FAN, You-Hong, MASRORPOUR, Fatemah, JING WANG, YUQIAO SHEN, MILLS, Gordon B, MINNA, John D, HEYMACH, John V

“…Small cell lung carcinoma (SCLC) is an aggressive malignancy affecting nearly 30,000 people annually in the United States. We have previously identified…”
Get full text

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer by Bartolacci, Caterina, Andreani, Cristina, Vale, Gonçalo, Berto, Stefano, Melegari, Margherita, Crouch, Anna Colleen, Baluya, Dodge L., Kemble, George, Hodges, Kurt, Starrett, Jacqueline, Politi, Katerina, Starnes, Sandra L., Lorenzini, Daniele, Raso, Maria Gabriela, Solis Soto, Luisa M., Behrens, Carmen, Kadara, Humam, Gao, Boning, Wistuba, Ignacio I., Minna, John D., McDonald, Jeffrey G., Scaglioni, Pier Paolo

“…Mutant KRAS (KM), the most common oncogene in lung cancer (LC), regulates fatty acid (FA) metabolism. However, the role of FA in LC tumorigenesis is still not…”
Get full text

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells by Kim, Jiyeon, Hu, Zeping, Cai, Ling, Li, Kailong, Choi, Eunhee, Faubert, Brandon, Bezwada, Divya, Rodriguez-Canales, Jaime, Villalobos, Pamela, Lin, Yu-Fen, Ni, Min, Huffman, Kenneth E., Girard, Luc, Byers, Lauren A., Unsal-Kacmaz, Keziban, Peña, Christopher G., Heymach, John V., Wauters, Els, Vansteenkiste, Johan, Castrillon, Diego H., Chen, Benjamin P. C., Wistuba, Ignacio, Lambrechts, Diether, Xu, Jian, Minna, John D., DeBerardinis, Ralph J.

“…In human cell lines with mutant KRAS and loss of LKB1, CPS1 expression correlates inversely with LKB1 expression; silencing CPS1 in these cells induces DNA…”
Get full text

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience by Sholl, Lynette M, Aisner, Dara L, Varella-Garcia, Marileila, Berry, Lynne D, Dias-Santagata, Dora, Wistuba, Ignacio I, Chen, Heidi, Fujimoto, Junya, Kugler, Kelly, Franklin, Wilbur A, Iafrate, A John, Ladanyi, Marc, Kris, Mark G, Johnson, Bruce E, Bunn, Paul A, Minna, John D, Kwiatkowski, David J

“…Molecular genetic analyses of lung adenocarcinoma have recently become standard of care for treatment selection. The Lung Cancer Mutation Consortium was formed…”
Get more information

Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment by Leroy, Bernard, Girard, Luc, Hollestelle, Antoinette, Minna, John D., Gazdar, Adi F., Soussi, Thierry

“…ABSTRACT Tumor‐derived cell lines play an important role in the investigation of tumor biology and genetics. Across a wide array of studies, they have been…”
Get full text

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers by Augustyn, Alexander, Borromeo, Mark, Wang, Tao, Fujimoto, Junya, Shao, Chunii, Dospoy, Patrick D., Lee, Victoria, Tan, Christopher, Sullivan, James P., Larsen, Jill E., Girard, Luc, Behrens, Carmen, Wistuba, Ignacio I., Xie, Yang, Cobb, Melanie H., Gazdar, Adi F., Johnson, Jane E., Minna, John D.

“…Aggressive neuroendocrine lung cancers, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), represent an understudied tumor subset…”
Get full text

SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures by Tlemsani, Camille, Pongor, Lorinc, Elloumi, Fathi, Girard, Luc, Huffman, Kenneth E., Roper, Nitin, Varma, Sudhir, Luna, Augustin, Rajapakse, Vinodh N., Sebastian, Robin, Kohn, Kurt W., Krushkal, Julia, Aladjem, Mirit I., Teicher, Beverly A., Meltzer, Paul S., Reinhold, William C., Minna, John D., Thomas, Anish, Pommier, Yves

“…CellMiner-SCLC (https://discover.nci.nih.gov/SclcCellMinerCDB/) integrates drug sensitivity and genomic data, including high-resolution methylome and…”
Get full text

A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients by Tang, Hao, Xiao, Guanghua, Behrens, Carmen, Schiller, Joan, Allen, Jeffrey, Chow, Chi-Wan, Suraokar, Milind, Corvalan, Alejandro, Mao, Jianhua, White, Michael A, Wistuba, Ignacio I, Minna, John D, Xie, Yang

“…Prospectively identifying who will benefit from adjuvant chemotherapy (ACT) would improve clinical decisions for non-small cell lung cancer (NSCLC) patients…”
Get full text